TY - JOUR
T1 - In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan
AU - Miyashita, Naoyuki
AU - Kobayashi, Intetsu
AU - Higa, Futoshi
AU - Aoki, Yosuke
AU - Kikuchi, Toshiaki
AU - Seki, Masafumi
AU - Tateda, Kazuhiro
AU - Maki, Nobuko
AU - Uchino, Kazuhiro
AU - Ogasawara, Kazuhiko
AU - Kurachi, Satoe
AU - Ishikawa, Tatsuya
AU - Ishimura, Yoshito
AU - Kanesaka, Izumo
AU - Kiyota, Hiroshi
AU - Watanabe, Akira
N1 - Funding Information:
Akira Watanabe has received speaker honoraria from MSD K.K., Kobayashi Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., UCB Japan Co. Ltd., AbbVie GK and GlaxoSmithKline K.K.; donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd.; payments for manuscript drafting and editing from Iyaku (Medicine and Drug) Journal Co., Ltd.; and grant support from Kyorin Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Fujifilm Pharma Co., Ltd., and Meiji Seika Pharma Co., Ltd.
Funding Information:
Hiroshi Kiyota has received grant support from Taisho Toyama Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc. and Taiho Pharmaceutical Co., Ltd.
Funding Information:
Yosuke Aoki has received speaker honoraria from MSD K.K., Shionogi & Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd.; and grant support from Shionogi & Co., Ltd .
Funding Information:
Toshiaki Kikuchi has received grant support from Chugai Pharmaceutical Co., Ltd. , Boehringer Ingelheim Japan, Inc. , Daiichi Sankyo Co., Ltd. , Ono Pharmaceutical Co., Ltd. and Astellas Pharma Inc .
Funding Information:
Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd. , grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc. , Taiho Pharmaceutical Co., Ltd. , Taisho Toyama Pharmaceutical Co., Ltd. , Japan Blood Products Organization , Asahi Kasei Pharma Corporation , Sumitomo Dainippon Pharma Co., Ltd. , Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd. , and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd. , GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K.
Funding Information:
Kazuhiro Tateda has received speaker honoraria from Pfizer Japan Inc., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Meiji Seika Pharma Co., Ltd. and Taisho Toyama Pharmaceutical Co., Ltd.; research funding from Otsuka Pharmaceutical Co., Ltd., grant support from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Japan Blood Products Organization, Asahi Kasei Pharma Corporation, Sumitomo Dainippon Pharma Co., Ltd., Shionogi & Co., Ltd., Meiji Seika Pharma Co., Ltd., and Toyama Pharmaceutical Co., Ltd.; and donations from Kyorin Pharmaceutical Co., Ltd., GlaxoSmithKline K.K., Astellas Pharma Inc., Meiji Seika Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and MSD K.K.
Publisher Copyright:
© 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2018/5
Y1 - 2018/5
N2 - The activities of various antibiotics against 58 clinical isolates of Legionella species were evaluated using two methods, extracellular activity (minimum inhibitory concentration [MIC]) and intracellular activity. Susceptibility testing was performed using BSYEα agar. The minimum extracellular concentration inhibiting intracellular multiplication (MIEC) was determined using a human monocyte-derived cell line, THP-1. The most potent drugs in terms of MICs against clinical isolates were levofloxacin, garenoxacin, and rifampicin with MIC90 values of 0.015 μg/ml. The activities of ciprofloxacin, pazufloxacin, moxifloxacin, clarithromycin, and azithromycin were slightly higher than those of levofloxacin, garenoxacin, and rifampicin with an MIC90 of 0.03–0.06 μg/ml. Minocycline showed the highest activity, with an MIC90 of 1 μg/ml. No resistance against the antibiotics tested was detected. No difference was detected in the MIC distributions of the antibiotics tested between L. pneumophila serogroup 1 and L. pneumophila non-serogroup 1. The MIECs of ciprofloxacin, pazufloxacin, levofloxacin, moxifloxacin, garenoxacin, clarithromycin, and azithromycin were almost the same as their MICs, with MIEC90 values of 0.015–0.06 μg/ml, although the MIEC of minocycline was relatively lower and that of rifampicin was higher than their respective MICs. No difference was detected in the MIEC distributions of the antibiotics tested between L. pneumophila serogroup 1 and L. pneumophila non-serogroup 1. The ratios of MIEC:MIC for rifampicin (8) and pazufloxacin (2) were higher than those for levofloxacin (1), ciprofloxacin (1), moxifloxacin (1), garenoxacin (1), clarithromycin (1), and azithromycin (1). Our study showed that quinolones and macrolides had potent antimicrobial activity against both extracellular and intracellular Legionella species. The present data suggested the possible efficacy of these drugs in treatment of Legionella infections.
AB - The activities of various antibiotics against 58 clinical isolates of Legionella species were evaluated using two methods, extracellular activity (minimum inhibitory concentration [MIC]) and intracellular activity. Susceptibility testing was performed using BSYEα agar. The minimum extracellular concentration inhibiting intracellular multiplication (MIEC) was determined using a human monocyte-derived cell line, THP-1. The most potent drugs in terms of MICs against clinical isolates were levofloxacin, garenoxacin, and rifampicin with MIC90 values of 0.015 μg/ml. The activities of ciprofloxacin, pazufloxacin, moxifloxacin, clarithromycin, and azithromycin were slightly higher than those of levofloxacin, garenoxacin, and rifampicin with an MIC90 of 0.03–0.06 μg/ml. Minocycline showed the highest activity, with an MIC90 of 1 μg/ml. No resistance against the antibiotics tested was detected. No difference was detected in the MIC distributions of the antibiotics tested between L. pneumophila serogroup 1 and L. pneumophila non-serogroup 1. The MIECs of ciprofloxacin, pazufloxacin, levofloxacin, moxifloxacin, garenoxacin, clarithromycin, and azithromycin were almost the same as their MICs, with MIEC90 values of 0.015–0.06 μg/ml, although the MIEC of minocycline was relatively lower and that of rifampicin was higher than their respective MICs. No difference was detected in the MIEC distributions of the antibiotics tested between L. pneumophila serogroup 1 and L. pneumophila non-serogroup 1. The ratios of MIEC:MIC for rifampicin (8) and pazufloxacin (2) were higher than those for levofloxacin (1), ciprofloxacin (1), moxifloxacin (1), garenoxacin (1), clarithromycin (1), and azithromycin (1). Our study showed that quinolones and macrolides had potent antimicrobial activity against both extracellular and intracellular Legionella species. The present data suggested the possible efficacy of these drugs in treatment of Legionella infections.
KW - Extracellular activity
KW - Intracellular activity
KW - Legionella species
KW - Minimum extracellular concentration inhibiting intracellular multiplication (MIEC)
KW - Minimum inhibitory concentration (MIC)
UR - http://www.scopus.com/inward/record.url?scp=85042112267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042112267&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2018.01.018
DO - 10.1016/j.jiac.2018.01.018
M3 - Article
AN - SCOPUS:85042112267
VL - 24
SP - 325
EP - 329
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
SN - 1341-321X
IS - 5
ER -